leadf
logo-loader
viewGenedrive PLC

Genedrive's David Budd hails CE mark for its infant hearing loss test

Genedrive PLC’s (LON:GDR) David Budd speaks to Proactive London's Andrew Scott soon after announcing their test for recognising the risk of antibiotic-induced hearing loss in infants obtained a European standard CE marking.

The kit will be used in critical care settings to screen babies for a genetic mutation, MT-RNR1, which if present, can cause lifelong deafness if they are prescribed with the antibiotic gentamicin.

Quick facts: Genedrive PLC

Price: 125.2 GBX

AIM:GDR
Market: AIM
Market Cap: £69.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20

2 min read